Stachyose increases intestinal barrier through Akkermansia muciniphila and reduces gut inflammation in germ-free mice after human fecal transplantation

Xi, Menglu; Jian, Li; Guo, Hao; An, Xiaopeng; Song, Yuxuan; Wei, Hong; Ge, Wupeng

doi:10.1016/j.foodres.2020.109288

Cited by 36 publications

(21 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results indicate that stachyose promotes the proliferation of Bifidobacterium, Akkermansia, and Blautia, regulates the bile acid metabolism pathway and the glycerin phospholipid metabolic pathway, and upregulates the expression of SCFAs, taurocholate, and sphingomyelin, thus protecting the intestinal barrier, increasing tight binding characteristics, and reducing intestinal inflammation. This conclusion is consistent with the findings of Xi et al, 35 who found that stachyose could down-regulate the expression of proinflammatory factors such as IL-1, IL-6 and TNF-⊍, increase the intestinal tight binding protein (occludin and ZO-1), and enhance the intestinal barrier. This study provides a certain mechanism for exploring the protective effect of stachyose from the level of the metabolic pathway.…”

Section: Discussionsupporting

confidence: 93%

Microbiome‐metabolomic analyses of the impacts of dietary stachyose on fecal microbiota and metabolites in infants intestinal microbiota‐associated mice

Tang

Zhang

et al. 2021

J Sci Food Agric

Self Cite

View full text Add to dashboard Cite

BACKGROUND: The intestinal microbiota and metabolites play an important role in human health and immunity. However, few studies have investigated the long-term effects of stachyose on the human intestinal microbiota and metabolism. Therefore, in this study, the feces of infants were transplanted into germ-free mice, and the effect of long-term stachyose intake on intestinal metabolism was examined by comparing the results of microbiome and metabolome analyses. Ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) was used to study the effects of stachyose intake on the metabolites and metabolic pathways of the transplanted human intestinal microbiota. RESULTS:We observed that stachyose significantly altered the composition of the intestinal microbiota and metabolites, upregulated production of the metabolite taurocholic acid, down-regulated amino acid metabolism, and significantly regulated the metabolism of taurine and hydroxytaurine, pantothenate and coenzyme A (CoA) biosynthesis, and other signaling pathways.CONCLUSION: These findings may provide a basis for elucidating the mechanism by which stachyose promotes host health.

show abstract

Section: Discussionsupporting

confidence: 93%

Microbiome‐metabolomic analyses of the impacts of dietary stachyose on fecal microbiota and metabolites in infants intestinal microbiota‐associated mice

Tang

Zhang

et al. 2021

J Sci Food Agric

Self Cite

View full text Add to dashboard Cite

show abstract

“…Integrity of the mucosal barrier can be disrupted by dysbiosis of the microbiome caused by inflammation, infections, antibiotic usage, western diet, or alcohol consumption [41,[45][46][47][48][49][50][51]. The mucus layer interacts with the microbiome and lower abundance of Akkermansia muciniphila was shown to decrease the mucus film [52][53][54][55][56][57]. An impaired gut barrier allows microbes and PAMPs to pass and reach the liver via the portal vein [34].…”

Section: Introductionmentioning

confidence: 99%

The Gut-Liver Axis in Cholestatic Liver Diseases

Blesl

Stadlbauer

2021

Nutrients

View full text Add to dashboard Cite

The gut-liver axis describes the physiological interplay between the gut and the liver and has important implications for the maintenance of health. Disruptions of this equilibrium are an important factor in the evolution and progression of many liver diseases. The composition of the gut microbiome, the gut barrier, bacterial translocation, and bile acid metabolism are the key features of this cycle. Chronic cholestatic liver diseases include primary sclerosing cholangitis, the generic term secondary sclerosing cholangitis implying the disease secondary sclerosing cholangitis in critically ill patients and primary biliary cirrhosis. Pathophysiology of these diseases is not fully understood but seems to be multifactorial. Knowledge about the alterations of the gut-liver axis influencing the pathogenesis and the outcome of these diseases has considerably increased. Therefore, this review aims to describe the function of the healthy gut-liver axis and to sum up the pathological changes in these cholestatic liver diseases. The review compromises the actual level of knowledge about the gut microbiome (including the mycobiome and the virome), the gut barrier and the consequences of increased gut permeability, the effects of bacterial translocation, and the influence of bile acid composition and pool size in chronic cholestatic liver diseases. Furthermore, therapeutic implications and future scientific objectives are outlined.

show abstract

“…Akkermansia is the only member of the Verrucomicrobia phylum and has been regarded as a novel microbe with probiotic properties [42]. Several studies have provided evidence that Akkermansia can improve mucus thickness in the inner layer, enhance the number of goblet cells, and promote the expression profiles of tight junction proteins of epithelial cells, such as the claudin-family, ZO-1, and occludin, in obese mice and alcohol-induced fatty liver mice [43,44]. The development of IBD is negatively associated with the abundance of Akkermansia [45].…”

Section: Discussionmentioning

confidence: 99%

Anti-Osteoporotic Effect of Lactobacillus brevis AR281 in an Ovariectomized Mouse Model Mediated by Inhibition of Osteoclast Differentiation

Hang

Sun

et al. 2022

Biology

View full text Add to dashboard Cite

Osteoporosis is a global disease characterized by weakened bone microarchitecture, leading to osteoporotic fractures. Estrogen replacement therapy is the traditional treatment for osteoporosis but carries with it an increased risk of cardiac events. In search of a safe and effective treatment, we used Lactobacillus brevis AR281, which has anti-inflammatory properties, to conduct a 7-week experiment, investigating its inhibitory effects on osteoporosis in an ovariectomized (ovx) mouse model. The results demonstrated that AR281 significantly improved bone microarchitecture and biomechanical strength in ovx mice by attenuating bone resorption. AR281 significantly decreased the critical osteoclast activator, the ratio of the receptor activator for nuclear factor kappa B (NF-κB) ligand (RANKL) to osteoprotegerin, and pro-inflammatory osteoclastogenic mediators, such as IL-1, IL-6, and IL-17, which can increase the RANKL expression. Moreover, AR281 modulated intestinal microbiota in ovx mice increased the abundance of Akkermansia, which is responsible for the improvement of gut epithelial barrier integrity. In an in vitro trial, AR281 suppressed the number of osteoclasts differentiated from the osteoclast precursor RAW264.7 cells caused by RANKL through the tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6)/NF-κB/nuclear factor of activated T cells c1 (NFATc1) pathway. Therefore, AR281 may be a natural alternative for combating osteoporosis.

show abstract

Stachyose increases intestinal barrier through Akkermansia muciniphila and reduces gut inflammation in germ-free mice after human fecal transplantation

Cited by 36 publications

References 37 publications

Microbiome‐metabolomic analyses of the impacts of dietary stachyose on fecal microbiota and metabolites in infants intestinal microbiota‐associated mice

Microbiome‐metabolomic analyses of the impacts of dietary stachyose on fecal microbiota and metabolites in infants intestinal microbiota‐associated mice

The Gut-Liver Axis in Cholestatic Liver Diseases

Anti-Osteoporotic Effect of Lactobacillus brevis AR281 in an Ovariectomized Mouse Model Mediated by Inhibition of Osteoclast Differentiation

Contact Info

Product

Resources

About